United States was Bio-Rad Laboratories’s largest region in fiscal 2025, bringing in $2.05B of $5.17B (40%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.31B | $2.24B | $2.08B | $2.05B | |||||||||||||
| Europe | $1.70B | $1.64B | $1.67B | $1.76B | |||||||||||||
| Segement Geographical Group Europe | — | — | — | — | |||||||||||||
| Asia | $1.28B | $1.13B | $1.04B | $1.03B | |||||||||||||
| Pacific Rim | — | — | — | — | |||||||||||||
| Segment Geographcial Group Pacific Rim | — | — | — | — | |||||||||||||
| Other (Primarily Canada & Latin America) | $310.80M | $333.00M | $338.60M | $330.80M | |||||||||||||
| Segment, Geographical, Groups Of Countries, Group Four | — | — | — | — | |||||||||||||
| Total | $5.60B | $5.34B | $5.13B | $5.17B |
Bio-Rad Laboratories brought in $5.17B from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 0.7% from $5.13B in fiscal 2024. United States was the largest at $2.05B (39.6%), ahead of Europe at $1.76B (34.1%) and Asia at $1.03B (19.9%). The remaining region, Other (Primarily Canada & Latin America), brought in $330.80M.
Compared with fiscal 2024, Europe grew fastest, up 5.7% to $1.76B, while Other (Primarily Canada & Latin America) fell the most, down 2.3% to $330.80M. From fiscal 2022 to 2025, combined revenue from these regions fell from $5.60B to $5.17B, a compound annual decline of 2.7%. United States' share of the total fell from 41.2% to 39.6%.
Clinical Diagnostics was Bio-Rad Laboratories’s largest segment in fiscal 2025, bringing in $3.12B of $5.17B (60%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | $2.90B | $2.98B | $3.08B | $3.12B | |||||||||||||
| Life Science | $2.69B | $2.36B | $2.06B | $2.04B | |||||||||||||
| All Other Segments | $8.00M | $7.00M | $1.00M | — | |||||||||||||
| Total | $5.60B | $5.34B | $5.13B | $5.17B |
Bio-Rad Laboratories brought in $5.17B from its two segments in fiscal 2025, the year ended December 31, 2025. Bio-Rad Laboratories regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $5.13B. Clinical Diagnostics was the largest at $3.12B (60.5%), ahead of Life Science at $2.04B (39.5%).
Compared with fiscal 2024, Clinical Diagnostics grew 1.6% to $3.12B, while Life Science fell 0.7% to $2.04B.
Bio-Rad Laboratories stopped reporting All Other Segments as a separate segment after fiscal 2024, when it brought in $1.00M.
Scenario, Previously Reported was Bio-Rad Laboratories’s largest revenue line in fiscal 2017, bringing in $1.07B of $1.07B (100%).
| Nature of Error | FY 2012 | FY 2012 | FY 2012 | FY 2013 | FY 2013 | FY 2013 | FY 2016 | FY 2016 | FY 2016 | FY 2017 | FY 2017 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scenario, Previously Reported | $942.40M | $1.03B | $1.02B | $1.00B | $1.01B | $1.07B | ||||||
| Scenario, Actual | — | — | — | — | — | — | ||||||
| Scenario, Adjustment | — | — | — | — | — | -$1.80M | ||||||
| Total | $942.40M | $1.03B | $1.02B | $1.00B | $1.01B | $1.07B |
Bio-Rad Laboratories brought in $1.07B from its two revenue lines in fiscal 2017, the year ended September 30, 2017. Bio-Rad Laboratories regrouped these revenue lines after fiscal 2017, so the total does not compare directly with that year's $1.01B. Scenario, Previously Reported was the largest at $1.07B (100.2%).
Bio-Rad Laboratories began breaking out Scenario, Adjustment in fiscal 2017, when it brought in -$1.80M. The total is net of Scenario, Adjustment, which took $1.80M off revenue in fiscal 2017.
Bio-Rad Laboratories (BIO) reports its revenue by geography, by segment and by nature of error. In fiscal 2025, United States was its largest region, bringing in $2.05B (39.6% of the total), followed by Europe at $1.76B (34.1%).
United States was Bio-Rad Laboratories' largest region in fiscal 2025, bringing in $2.05B, or 39.6% of the $5.17B total across its four regions.
Clinical Diagnostics was Bio-Rad Laboratories' largest segment in fiscal 2025, bringing in $3.12B, or 60.5% of the $5.17B total across its two segments.
Scenario, Previously Reported was Bio-Rad Laboratories' largest revenue line in fiscal 2017, bringing in $1.07B, or 100.2% of the $1.07B total across its two revenue lines.
Among Bio-Rad Laboratories' regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 5.7% from $1.67B to $1.76B.
Every figure comes from Bio-Rad Laboratories' annual financial filings, as reported. Each line keeps the name Bio-Rad Laboratories gives it, and years follow its fiscal calendar.
Bio-Rad Laboratories' revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.